GENERAL COMMENTS
This is an interesting study, well-designed and methodologically sound. Inflammatory rheumatic diseases are associated with accelerated atherosclerosis. Patients with these conditions exhibit a dyslipidemia pattern. Lipoprotein(a) is now considered as an independent risk factor for atherosclerotic disease. Therefore, studies focused on this issue are of potential interest. Although at a first glance the sample size might appear relatively small, data are robust enough to compensate for this potential limitation.
Results shown by the authors indicate that in patients with inflammatory arthritis high levels of Lp(a) are positively correlated with CRP. This result is in line with previous studies that supported the influence of inflammation, measured by CRP, in the development of subclinical atherosclerosis (Ref.
High-grade Creactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol. 2005 Jul;32(7):1219-23) and cardiovascular events/ cardiovascular death (HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum. 2007 Feb 15; 57(1):125-32) , in patients with rheumatoid arthritis. Discuss these studies in the setting of the results in the section of Discussion). Also, in the Discussion, make a comment (Discuss further) on the potential beneficial effect of therapies that reduce Lp(a). It is especially true for the anti-IL-6 receptor tocilizumab. They found that CAD/IRD patients had higher Lp(a) levels compared that in CAD alone and HC and there was a strong correlation of Lp(a) with C-reactive protein (CRP) in those with hgih Lp(a) levels. They concluded that anti-inflmmatory treatment could be considerd in patients with CAD/IRD. Although study touches on a very timely topic and has the potential to add an important incremental step to the literature, the enrolled populations may be a key limitation, especially CAD alone and HC. Were their patients consecutively enrolled? why authors did not use a case-control study with matched age and gender for examining their hypothesis? Besides, sample size may be too small to make a conclusion due to strong influences by many confounders, for example, the severity of CAD, medications, death cause, even enrolled time of population. Hence, this reviewer considered that their findings basically might be not support their hypothesis at present analysis.
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GENERAL COMMENTS
The statistics of paper requires major revisions. First, matching process for CVD/IRD to CVD/non-IRD should be explained and adjusted for in the analysis; please see and cite the following paper: https://link.springer.com/article/10.1007/s10654-017-0325-0 Second, logistic regression model should be used to adjust for all potential confounders including age (but not limited to age) as well as matching variables based on matching protocol if matching is not paired. Third, adjusted odds ratios with 95% confidence intervals should be estimated and presented and the results should be interpreted in light of these estimates as well as P-values. Fourth, the limitations of the design including reverse causality should be acknowledged in the Discussion.
VERSION 1 -AUTHOR RESPONSE
Response to Reviewers
Reviewer #1
We thank the Reviewer for thorough and thoughtful evaluation of the manuscript as well as critical comments. We respond here in detail to each of the Reviewer's comments We share this valid concern of the Reviewer and in the revised version of the manuscript the role of inflammation as a driver of accelerated atherogenesis in patients with rheumatoid arthritis and related inflammatory disease have been discussed more thoroughly. In addition, the important articles pointed out by the reviewer are now included and commented on in the Discussion section.
Also, in the Discussion, make a comment (Discuss further) on the potential beneficial effect of therapies that reduce Lp(a). It is especially true for the anti-IL-6 receptor tocilizumab. Use for this purpose a recent paper based on an epidemiological study in RA patients who were undergoing tocilizumab therapy (Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project. J Clin Lipidol. 2017 May -Jun;11(3):749-756).
We agree with the Reviewer that the data from tocilizumab interventions in RA patients are clearly of interest, suggesting that tocilizumab treatment lowers Lp(a) levels. This was more recently confirmed in larger RCTs. In contrast, we recently showed no effects of tozilizumab on Lp(a) in RTC study in patients with Non-ST-elevation myocardial infarction (NSTEMI). The reasons for these apparently discrepancies is at present not clear, but could include more use of statins and shorter duration of therapy in the NSTEMI study. It is also possible that Lp(a) levels are differently regulated in IRD patients with a higher degree of systemic inflammation than in CAD patients without IRD. These important issues as raised by the Reviewer are now discussed in the revised manuscript, and we have also included additional references, including the interesting article in J Clin Lipidol.
Minor comments:
In the Introduction (first paragraph) you say "The reasons are not fully understood, but seem to involve chronic inflammation as a common mediator of both IRD and atherosclerosis". Please, add that besides chronic inflammation, traditional cardiovascular risk factors and a genetic component are also implicated in the increased risk of cardiovascular disease observed in patients with chronic inflammatory rheumatic diseases. The phrases in the Introduction have been changed according to the Reviewer´s comment and we have also included the article in Autoimmun Rev in the reference list.
Please, make a double check to the section of statistical analysis. There may be a typographic (minor) mistake (Page 9 line 9). Perhaps t the word "non-normally" should be removed from this line.
We thank the reviewer for this comment, and have corrected accordingly.
Page 10 (first paragraph): lines 3-5: You say "which could implicate that Lp(a) in this subgroup of patients could be influenced by inflammation and not only genetic factors." Try to be careful, it is possible that genetic factors may act regulating inflammation in patients with inflammatory arthritis (e.g. RA).
We agree with this comment and the sentence has now been changed to: "Whereas genetic factors influence Lp(a) levels and may also influence activation of inflammatory pathways, it is possible that inflammation per se also could modulate Lp(a) levels, at least in subgroup of individuals."
Reviewer: 2
We thank the Reviewer for thorough and thoughtful evaluation of the manuscript as well as for the critical and helpful comments. We respond here in detail to each of the reviewer's comments.
Although study touches on a very timely topic and has the potential to add an important incremental step to the literature, the enrolled populations may be a key limitation, especially CAD alone and HC.
Were their patients consecutively enrolled?
The patients were consecutively enrolled in all groups, and this information is now also added to the manuscript.
Why authors did not use a case-control study with matched age and gender for examining their hypothesis?
This is an important issue pointed out by the Reviewer. Both the IRD and non-IRD groups were matched and importantly, the comparisons between these two groups were the major aim of the study. The healthy control group was matched with the two patient groups for sex, but it was not feasible to include a large enough number of completely healthy old people (as old as our CVD groups). Therefore, although the control group and the patients had age within the same range, they were not totally matched for age. To account for this, we adjusted for age together with other confounders, such as sex, in our analyses (see also below). These issues have now been more clearly stated in the revised manuscript.
Besides, sample size may be too small to make a conclusion due to strong influences by many confounders, for example, the severity of CAD, medications, death cause, even enrolled time of population. Hence, this reviewer considered that their findings basically might be not support their hypothesis at present analysis.
We clearly agree that sample size is an issue in the present study and that important demographics that may influence Lp(a) levels need to be accounted for. In the revision we report adjusted data on the difference in Lp(a) levels between the different groups accounting for core demographics. First, we have performed a multi-nominal regression with controls as the reference group and Lp(a) (log transformed and normalized), age and gender as independent variables. This analysis mirrors the original analysis comparing these groups showing a significant association between CAD/IRD and LP(a) (p=0.037) and trend for the CAD alone group (p=0.080). Thus, the higher levels in the CAD groups, is not due to age and gender differences between the studied groups. Second, for comparing the CAD +/-IRD groups we have performed a logistic regression in the CAD groups with +/-IRD as dependent variable and blockwise inclusion of relevant clinical data (in addition to Lp(a)). The OR for Lp(a) in this analysis in univariate analysis was 1.02 (95% CI: 0.70-1.48) p=0.91. This association remained nearly unchanged when including gender, age, family history of CAD, diabetes, NSAIDs, prednisolone or statin treatment. The combined model with all these demographics had an OR for Lp(a) of 1.03 (0.63-1.69) p=0.906. Indeed, as reported in the previous submission, Lp(a) clearly correlated poorly with any demographic, and it is not surprising that the difference between CAD patients with and without IRD was unmodified when adjusting for these variables. Moreover, as can be seen in Figure 1 ., both CAD groups appear to be characterized by a sub-population with elevated Lp(a) where the association between Lp(a) and cardio-metabolic risk factors seems to be more prominent.
Taken together, these new analysis support that i) Lp(a) is increased in CAD compared to heathy controls and ii) in both CAD groups there appears to be a sub-population with increased Lp(a) that was associated with cardio-metabolic risk parameters including CRP. These new statistical approaches and conclusions have now been included in the revised manuscript.
Reviewer: 3
First, matching process for CVD/IRD to CVD/non-IRD should be explained and adjusted for in the analysis; please see and cite the following paper: https://link.springer.com/article/10.1007/s10654-017-0325-0 This is an important issue pointed out by the Reviewer. Both the IRD and non-IRD groups were matched and importantly, the comparisons between these two groups were major aim of the study. The healthy control group was matched with the two patient groups for sex, but it was not feasible to include a large enough number of completely healthy old people (as old as our CVD groups). Therefore, although the control group and the patients had age within the same range, they were not totally matched for age. To account for this, we adjusted for age together with other confounders, such as sex, in our analyses. See also below. These issues have now been more clearly stated in the revised manuscript. We also thank the Reviewer for the highly relevant citation that underscores the statistical challenges in case-control studies, and this article has now been included in the revised manuscript.
Second, logistic regression model should be used to adjust for all potential confounders including age (but not limited to age) as well as matching variables based on matching protocol if matching is not paired.
Third, adjusted odds ratios with 95% confidence intervals should be estimated and presented and the results should be interpreted in light of these estimates as well as P-values.
We fully agree with the Reviewer that some adjusted analysis is appropriate and that important demographics that may influence Lp(a) levels need to be accounted. In the revision we report adjusted data on the difference in Lp(a) levels between the different groups accounting for core demographics. First, we have performed a multi-nominal regression with controls as the reference group and Lp(a) (log transformed and normalized), age and gender as independent variables. This analysis mirrors the original analysis comparing these groups showing a significant association between CAD/IRD and LP(a) (p=0.037) and trend for the CAD alone group (p=0.080). Thus, the higher levels in the CAD groups, is not due to age and gender differences between the studied groups. Second, for comparing the CAD +/-IRD groups we have performed a logistic regression in the CAD groups with +/-IRD as dependent variable and block wise inclusion of relevant clinical data (in addition to Lp(a)). The OR for Lp(a) in this analysis in univariate analysis was 1.02 (95% CI: 0.70-1.48) p=0.91. This association remained nearly unchanged when including gender, age, family history of CAD, diabetes, NSAIDs, prednisolone or statin treatment. The combined model with all these demographics had an OR for Lp(a) of 1.03 (0.63-1.69) p=0.906. Indeed, as reported in the previous submission, Lp(a) clearly correlated poorly with any demographic, and it is not surprising that the difference between CAD patients with and without IRD was unmodified when adjusting for these variables. Moreover, as can be seen in Figure 1 ., both CAD groups appear to be characterized by a sub-population with elevated Lp(a) where the association between Lp(a) and cardio-metabolic risk factors seems to be more prominent.
Fourth, the limitations of the design including reverse causality should be acknowledged in the Discussion
We clearly agree with the Reviewer and in the revised version we have more clearly underscored the limitations of the study including the design and relatively low number of patients. We have also underscored that associations do not prove any causality.
